Literature DB >> 20348238

Immature osteoblast lineage cells increase osteoclastogenesis in osteogenesis imperfecta murine.

Haitao Li1, Xi Jiang, John Delaney, Tiziana Franceschetti, Ines Bilic-Curcic, Judy Kalinovsky, Joseph A Lorenzo, Danka Grcevic, David W Rowe, Ivo Kalajzic.   

Abstract

This study addressed the role of impairment of osteoblastic differentiation as a mechanism underlying pathophysiology of the osteogenesis imperfecta (OI). We hypothesized that combination of impaired osteogenic differentiation with increased bone resorption leads to diminished bone mass. By introducing visual markers of distinct stages of osteoblast differentiation, pOBCol3.6GFP (3.6GFP; preosteoblast) and pOBCol2.3GFP (2.3GFP; osteoblast/osteocytes), into the OIM model, we assessed osteoblast maturation and the mechanism of increased osteoclastogenesis. Cultures from oim/oim;2.3GFP mice showed a marked reduction of cells expressing GFP relative to +/+;2.3GFP littermates. No significant difference in expression of 3.6GFP between the +/+ and oim/oim mice was observed. Histological analysis of the oim/oim;3.6GFP mice showed an increased area of GFP-positive cells lining the endocortical surface compared with +/+;3.6GFP mice. In contrast GFP expression was similar between oim/oim;2.3GFP and +/+;2.3GFP mice. These data indicate that the osteoblastic lineage is under continuous stimulation; however, only a proportion of cells attain the mature osteoblast stage. Indeed, immature osteoblasts exhibit a stronger potential to support osteoclast formation and differentiation. We detected a higher Rankl/Opg ratio and higher expression of TNF-alpha in sorted immature osteoblasts. In addition, increased osteoclast formation was observed when osteoclast progenitors were cocultured with oim/oim-derived osteoblasts compared with osteoblasts derived from +/+ mice. Taken together, our data indicate that osteoblast lineage maturation is a critical aspect underlying the pathophysiology of OI.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20348238      PMCID: PMC2861105          DOI: 10.2353/ajpath.2010.090704

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  26 in total

1.  Expression profile of osteoblast lineage at defined stages of differentiation.

Authors:  Ivo Kalajzic; Ada Staal; Wen-Pin Yang; Yuli Wu; Susan E Johnson; Jean H M Feyen; Winfried Krueger; Peter Maye; Fang Yu; Yifang Zhao; Lynn Kuo; Rishi R Gupta; Luke E K Achenie; Hsin-Wei Wang; Dong-Guk Shin; David W Rowe
Journal:  J Biol Chem       Date:  2005-04-15       Impact factor: 5.157

2.  Histological analysis of GFP expression in murine bone.

Authors:  Xi Jiang; Zana Kalajzic; Peter Maye; Alen Braut; Justin Bellizzi; Mina Mina; David W Rowe
Journal:  J Histochem Cytochem       Date:  2005-05       Impact factor: 2.479

3.  Target cells in bone for parathormone and calcitonin are different: enrichment for each cell type by sequential digestion of mouse calvaria and selective adhesion to polymeric surfaces.

Authors:  G L Wong; D V Cohn
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

4.  Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.

Authors:  T Kon; T J Cho; T Aizawa; M Yamazaki; N Nooh; D Graves; L C Gerstenfeld; T A Einhorn
Journal:  J Bone Miner Res       Date:  2001-06       Impact factor: 6.741

5.  Col1a1-driven transgenic markers of osteoblast lineage progression.

Authors:  S Dacic; I Kalajzic; D Visnjic; A C Lichtler; D W Rowe
Journal:  J Bone Miner Res       Date:  2001-07       Impact factor: 6.741

6.  Use of type I collagen green fluorescent protein transgenes to identify subpopulations of cells at different stages of the osteoblast lineage.

Authors:  I Kalajzic; Z Kalajzic; M Kaliterna; G Gronowicz; S H Clark; A C Lichtler; D Rowe
Journal:  J Bone Miner Res       Date:  2002-01       Impact factor: 6.741

7.  Mechanisms of compensation of hemolytic anemia in a lactate dehydrogenase mouse mutant.

Authors:  J P Kremer; T Datta; W Pretsch; D J Charles; P Dörmer
Journal:  Exp Hematol       Date:  1987-07       Impact factor: 3.084

8.  NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1.

Authors:  Teruhito Yamashita; Zhenqiang Yao; Fang Li; Qian Zhang; I Raul Badell; Edward M Schwarz; Sunao Takeshita; Erwin F Wagner; Masaki Noda; Koichi Matsuo; Lianping Xing; Brendan F Boyce
Journal:  J Biol Chem       Date:  2007-05-07       Impact factor: 5.157

9.  Marrow stromal cells and osteoclast precursors differentially contribute to TNF-alpha-induced osteoclastogenesis in vivo.

Authors:  Hideki Kitaura; Mark S Sands; Kunihiko Aya; Ping Zhou; Teruhisa Hirayama; Brian Uthgenannt; Shi Wei; Sunao Takeshita; Deborah Veis Novack; Matthew J Silva; Yousef Abu-Amer; F Patrick Ross; Steven L Teitelbaum
Journal:  J Immunol       Date:  2004-10-15       Impact factor: 5.422

10.  Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors.

Authors:  Thomas E Uveges; Patricia Collin-Osdoby; Wayne A Cabral; Felicia Ledgard; Leah Goldberg; Clemens Bergwitz; Antonella Forlino; Philip Osdoby; Gloria A Gronowicz; Joan C Marini
Journal:  J Bone Miner Res       Date:  2008-12       Impact factor: 6.741

View more
  17 in total

1.  Skeletal cell YAP and TAZ combinatorially promote bone development.

Authors:  Christopher D Kegelman; Devon E Mason; James H Dawahare; Daniel J Horan; Genevieve D Vigil; Scott S Howard; Alexander G Robling; Teresita M Bellido; Joel D Boerckel
Journal:  FASEB J       Date:  2018-01-10       Impact factor: 5.191

2.  Myostatin deficiency partially rescues the bone phenotype of osteogenesis imperfecta model mice.

Authors:  A K Oestreich; S M Carleton; X Yao; B A Gentry; C E Raw; M Brown; F M Pfeiffer; Y Wang; C L Phillips
Journal:  Osteoporos Int       Date:  2015-07-16       Impact factor: 4.507

Review 3.  New perspectives on osteogenesis imperfecta.

Authors:  Antonella Forlino; Wayne A Cabral; Aileen M Barnes; Joan C Marini
Journal:  Nat Rev Endocrinol       Date:  2011-06-14       Impact factor: 43.330

4.  Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta.

Authors:  Youngjae Jeong; Salah A Daghlas; Yixia Xie; Molly A Hulbert; Ferris M Pfeiffer; Mark R Dallas; Catherine L Omosule; R Scott Pearsall; Sarah L Dallas; Charlotte L Phillips
Journal:  J Bone Miner Res       Date:  2018-06-22       Impact factor: 6.741

5.  Diverse osteoclastogenesis of bone marrow from mandible versus long bone.

Authors:  Thawinee Chaichanasakul; Benjamin Kang; Olga Bezouglaia; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Periodontol       Date:  2013-09-04       Impact factor: 6.993

6.  Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α.

Authors:  G Brunetti; F Papadia; A Tummolo; R Fischetto; F Nicastro; L Piacente; A Ventura; G Mori; A Oranger; I Gigante; S Colucci; M Ciccarelli; M Grano; L Cavallo; M Delvecchio; M F Faienza
Journal:  Osteoporos Int       Date:  2016-02-08       Impact factor: 4.507

7.  Splenomegaly, myeloid lineage expansion and increased osteoclastogenesis in osteogenesis imperfecta murine.

Authors:  Brya G Matthews; Emilie Roeder; Xi Wang; Hector Leonardo Aguila; Sun-Kyeong Lee; Danka Grcevic; Ivo Kalajzic
Journal:  Bone       Date:  2017-06-07       Impact factor: 4.398

8.  How tough is brittle bone? Investigating osteogenesis imperfecta in mouse bone.

Authors:  R O Ritchie; S J Shefelbine; A Carriero; E A Zimmermann; A Paluszny; S Y Tang; H Bale; B Busse; T Alliston; G Kazakia
Journal:  J Bone Miner Res       Date:  2014-06       Impact factor: 6.741

Review 9.  Visual reporters for study of the osteoblast lineage.

Authors:  Emilie Roeder; Brya G Matthews; Ivo Kalajzic
Journal:  Bone       Date:  2016-09-08       Impact factor: 4.398

10.  Potential of human fetal chorionic stem cells for the treatment of osteogenesis imperfecta.

Authors:  Gemma N Jones; Dafni Moschidou; Hassan Abdulrazzak; Bhalraj Singh Kalirai; Maximilien Vanleene; Suchaya Osatis; Sandra J Shefelbine; Nicole J Horwood; Massimo Marenzana; Paolo De Coppi; J H Duncan Bassett; Graham R Williams; Nicholas M Fisk; Pascale V Guillot
Journal:  Stem Cells Dev       Date:  2013-10-16       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.